Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376854 | 0.84 | ALDH1A1 (0.38) | CYP2A13ALDH1A1HTTPOLBL3MBTL1 | |
| SCHEMBL376997 | 0.84 | TAAR1 (0.35) | CYP2A13ALDH1A1TSHRPOLBTAAR1 | |
| SCHEMBL377003 | 0.84 | ALDH1A1 (0.38) | MAPK1CYP2A13MAOBALDH1A1TSHR | |
| SCHEMBL4821650 | 0.80 | MAOA (0.38) | MAPK1MAOBALDH1A1TSHRHTT | |
| SCHEMBL376479 | 0.79 | MAPK1 (0.41) | MAPK1CYP2A13MAOBALDH1A1TSHR | |
| SCHEMBL376968 | 0.76 | MEN1 (0.36) | ALDH1A1POLBTAAR1MEN1KMT2A | |
| SCHEMBL13504049 | 0.76 | ACHE (0.46) | ALDH1A1POLBTAAR1GAA | |
| SCHEMBL13503627 | 0.72 | SLC6A2 (0.36) | POLBTAAR1 | |
| SCHEMBL21427376 | 0.69 | MAPK1 (0.41) | MAPK1CYP2A13ALDH1A1TSHRHTT | |
| SCHEMBL376616 | 0.67 | LMNA (0.44) | POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | MAPK1 4107/4885CYP2A13 4087/4885MAOB 3196/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | MAPK1 4107/4885CYP2A13 4087/4885MAOB 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.